Neutrophilic eccrine hidradenitis induced by cetuximab

Cutaneous and Ocular Toxicology

Volumn 31, Issue 2, 2012, Pages 148-150

  Turan, Hakan ^a   Kaya, Ertugrul ^a   Gurlevik, Zehra ^a   Erdem, Havva ^a   Oktay, Murat ^a  

^a DUZCE UNIVERSITY   (Turkey)

Author keywords

Cetuximab; epidermal growth factor; neutrophilic eccrine hidradenitis

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHYLPREDNISOLONE; OXALIPLATIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; COLON ADENOCARCINOMA; DISEASE ASSOCIATION; HAND INJURY; HIDRADENITIS; HISTOPATHOLOGY; HUMAN; LEG INJURY; LYMPHOCYTIC INFILTRATION; MALE; NEUTROPHIL CHEMOTAXIS; NEUTROPHILIC ECCRINE HIDRADENITIS; OUTPATIENT DEPARTMENT; WRIST INJURY;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HIDRADENITIS; HUMANS; MALE; MIDDLE AGED;

EID: 84862096182     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.3109/15569527.2011.627077     Document Type: Article

References (8)

1. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
2. Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 2000;10:505-510.
3. Nanney LB, Stoscheck CM, King LE Jr, Underwood RA, Holbrook KA. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990;94:742-748.
4. Bachmeyer C, Aractingi S. Neutrophilic eccrine hidradenitis. Clin Dermatol 2000;18:319-330.
5. Ocvirk J, Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol 2010;24:453-459.
6. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55:657-670.
7. Peus D, Hamacher L, Pittelkow MR. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J Invest Dermatol 1997;109:751-756.
8. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169-1176.